O TYM ODCINKU

Język angielski
Stany Zjednoczone

TRANSKRYPCJA 🔗

WYSZUKAJ MINIONE ODCINKI

Wyszukaj minione odcinki IBCD 2016.

INNE ODCINKI W TYM PODCASCIE

Dr Gerstung speaks with ecancertv at IBCD 2016 about genetic analysis of AML patients that has contributed to a predictive model for treatment risk and outcomes. He describes how modelling can be improved with wider data gathering, across populations and tumour types, though this faces the risk of…
Dr Beer speaks with ecancertv at IBCD 2016 about making use of genomic data in a clinically actionable setting. He opens with comments on the work of Dr Moritz Gerstung and considers the issues of storage, access and regulation in genomic libraries. Dr Beer describes how unregulated access and of…
Dr Schneider speaks with ecancertv at IBCD 2016 about the regulatory checkpoints to be passed in the development of assays. He highlights the difference in reproducibility and robustness of research and clinical assays, the clinical utility of validated biomarkers, and how beginning assay developm…
Dr Malik speaks with ecancertv at IBCD 2016 to discuss the work of the National Cancer Institute in recruiting patients to clinical trials when subtyping limits disease-wide enrollment. She describes how 'exceptional responders' can be referred to the NCI for genotyping, and schemes to match patie…
Zastrzeżenie: Podcast i grafika osadzone na tej stronie pochodzą z ecancer.org, który jest własnością jego właściciela i nie jest powiązany ani wspierany przez Listen Notes, Inc.